(DNA) Alert: Did You Lose Money on Your Ginkgo Bioworks Investment? Contact Johnson Fistel Regarding Investigation
SAN DIEGO- GlobeNewswire—October 6, 2021
Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by Ginkgo Bioworks Holdings, Inc. (NYSE: DNA).
Ginkgo Bioworks went public via a deSPAC transaction with blank check company Soaring Eagle Acquisition Corporation in September 2021.
On October 6, 2021, Scorpion Capital, a short seller, released a report stating Ginkgo Bioworks is a “colossal scam.” Within the report, Scorpion says that, “We believe that Ginkgo is concealing the true extent of its dependence on related party revenue and that it is even greater than it reports. We have uncovered a smoking gun that indicates that essentially all of its foundry revenue is derived from related parties.”
Following this news, Ginkgo Bioworks’ stock price fell over 20% in early morning trading on October 6, 2021.
If you have information that could assist in this investigation, including past employees and others, or a Ginkgo Bioworks Holdings shareholder and are interested in learning more about the investigation, please contact Jim Baker ([email protected]) by email or phone at 619-814-4471. If emailing, please include a phone number.
Additionally, you can [click here to join this action]. There is no cost or obligation to you.
About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit https://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.